Beijing Science Sun Pharmaceutical Co Ltd (300485) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Beijing Science Sun Pharmaceutical Co Ltd stock ¥0.67, price ¥6.70, that is 90.0% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Beijing Science Sun Pharmaceutical Co Ltd
300485 · SHEFar too expensive (fair value 90% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.
How to read this chart
60‑month range ¥5.85 – ¥18.01 · fair‑value band ¥0.5 – ¥0.83 · the ¥6.70 price screens above the ¥0.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.
Every Wednesday you see whether Beijing Science Sun Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, and other drugs.
Show moreShow less
It is also involved in raw materials, solid oral preparations, and health products; extraction of traditional Chinese medicine; manufacture of Chinese and Western medicine preparations; research, development, production, and sales of tablets, hard capsules, powders, granules, and active pharmaceutical ingredients; outward investment, technology introduction and exchange, international business development, livestock and poultry production, and research and development of bio-organic fertilizers and bio-feeds.
In addition, the company is engaged venture capital; equity investment through private equity funds; technology development, transfer, and services for biological products, pharmaceuticals, diagnostic reagents, and medical devices; biotechnology information consulting; sales of immunoassay reagents and laboratory instruments; research, development and industrialization of human vaccines; investment management and consulting for non-securities businesses, as well as inspection and testing services, consulting services, and health food production.
The company was founded in 1999 and is headquartered in Beijing, China.
Stock analysis
Beijing Science Sun Pharmaceutical Co Ltd (300485) currently trades at ¥6.70, while our model-based Fair Value estimate is ¥0.67, 90% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥4.33 per share, and 1 of the 8 models we run sit above the ¥6.70 price.
Bear case: the Earnings-Based group reads lowest at ¥0.25, and 7 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.5 (bear) to ¥0.83 (bull), the price of ¥6.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Beijing Science Sun Pharmaceutical Co Ltd reported revenue of 405M CNY in FY2025 versus 1.1B CNY in FY2021, a compound −21.2%/yr. Reported net income was 14.6M CNY in FY2025, compounding −56.4%/yr from FY2021.
Key figures
Market cap 3.3B CNY (≈ $495M) Small · P/S ratio 10.2 · EPS (TTM) ¥-0.35 · Dividend yield 4.5% · Net margin −46.5% · Return on equity −5.2% · Return on assets (EBIT) 4.2% (5-year average) · Operating margin −8.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −90%, 300485 screens richer than that median.
Fair Value models
All 8 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
300485 screens overvalued: fair value 90% below the price. Compare with Merck KGaA →
Compare Beijing Science Sun Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 610 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $79.11 | $113.53 | +44% | vs 300485 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.00 | ¥52.43 | +12% | vs 300485 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,884.90 | ₹1,982.92 | +5% | vs 300485 |
| Haleon plc HLN | $9.07 | $8.47 | −7% | vs 300485 |
| Merck KGaA MRK | €146.45 | €108.83 | −26% | vs 300485 |
| Galderma Group GALD | CHF 182.85 | CHF 112.84 | −38% | vs 300485 |
| Teva Pharmaceutical Industries Limited TEVA | $39.23 | $20.74 | −47% | vs 300485 |
| Takeda Pharmaceutical Company TAK | $21.77 | $11.26 | −48% | vs 300485 |
| Sandoz Group SDZ | CHF 80.50 | CHF 41.06 | −49% | vs 300485 |
| Divi's Laboratories Limited DIVISLAB | ₹11,180.50 | ₹1,566.89 | −86% | vs 300485 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Beijing Science Sun Pharmaceutical Co Ltd (300485) overvalued or undervalued?
What is the fair value of 300485?
What is the quality score of 300485?
What is the price target for Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the Beijing Science Sun Pharmaceutical Co Ltd stock forecast for 2026?
What is the revenue of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
Does Beijing Science Sun Pharmaceutical Co Ltd pay a dividend?
How much is the dividend of Beijing Science Sun Pharmaceutical Co Ltd (300485) and when is the ex-dividend date?
What is the intrinsic value of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
Is Beijing Science Sun Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 300485?
How much is Beijing Science Sun Pharmaceutical Co Ltd worth?
What do the bullish and bearish scenarios say about 300485?
How solid is the balance sheet of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
How far is 300485 from its 52-week high?
Which stocks are comparable to Beijing Science Sun Pharmaceutical Co Ltd?
Is Beijing Science Sun Pharmaceutical Co Ltd stock attractive at the current price?
How is the fair value of 300485 calculated?
Is it still worth investing in stocks now?
What is the share price of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What should I pay attention to with Beijing Science Sun Pharmaceutical Co Ltd right now?
Where does the earnings growth of Beijing Science Sun Pharmaceutical Co Ltd (300485) come from?
Key figures of Beijing Science Sun Pharmaceutical Co Ltd
How large is the market capitalisation of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the P/S ratio of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What are the earnings per share of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the dividend yield of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the net margin of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the return on equity of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the EBIT return on assets of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
What is the operating margin of Beijing Science Sun Pharmaceutical Co Ltd (300485)?
How fast is revenue growing at Beijing Science Sun Pharmaceutical Co Ltd (300485)?
How fast are earnings growing at Beijing Science Sun Pharmaceutical Co Ltd (300485)?
How much free cash flow does Beijing Science Sun Pharmaceutical Co Ltd (300485) generate?
How much net cash does Beijing Science Sun Pharmaceutical Co Ltd (300485) hold?
Watch Beijing Science Sun Pharmaceutical Co Ltd in the live analysis
One click puts Beijing Science Sun Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.